Abstract: A system, method, and apparatus for annotating an electronic document independently of its content is provided. According to one variation, a tablet and stylus-based computer is programmed with a document browser that permits a user to annotate documents viewed through the browser. The annotations are stored separately from the viewed document pages but are correlated with the pages such that when a previously annotated page is revisited, annotations relating to that page are retrieved and displayed on top of the page as an “ink” layer. Three different annotation modes are possible: ink, highlight, and erase. Each mode can be selected through a user interface supplied through the browser or through controls embedded in a document.

Abstract: A feed having a waveguide with a longitudinal axis. A plurality of corrugations extending from an end of the waveguide. The corrugations coaxial with the longitudinal axis, forming an extension of the waveguide. The corrugations having an end face angle less than 90 degrees with respect to the longitudinal axis to squint the feed beam.

Abstract: A multi-beam feed assembly having a feed assembly housing with a plurality of input waveguide(s) formed in a front face. The housing may be adapted for manufacture via die casting. The housing also having at least two PCB mounting surface(s), a plurality of probe aperture(s) through the housing between the input waveguide(s) and at least one of the PCB mounting surface(s) and at least one interconnect waveguide through the housing between two of the PCB mounting surface(s). A plurality of PCB may be coupled to the housing at the PCB mounting surfaces. A plurality of transition probe(s) located in the probe aperture(s) coupling each input waveguide to one of the plurality of the PCB and the at least one interconnect waveguide between the at least two PCB mounting surfaces coupling signals between the PCB.

Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

Abstract: A waveguide for use with a dual polarization waveguide probe system is described which provides an improved frequency response across a desired frequency range (10.7 to 12.75 GHz) and particularly at the band edges. This is achieved by providing a waveguide with a rotator that incorporates a reflector plate in combination with a differential phase shifter in the form of a waveguide of slightly asymmetrical cross section so that orthogonal signals which travel through this portion have a different cut-off wavelength. This results in a rotator which achieves 180° of phase shift between two orthogonal components across the frequency range of signals received by the waveguide. The reflector plate and the differential phase shifter have inverse frequency characteristics so that the combined phase shift characteristic of the rotator has a flatter frequency characteristic.

Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

Abstract: A method and apparatus for energizing a multi-channel LNBF containing multiple LNB(s) the LNBF connected to multiple IRDs. The number of IRDs present is detected. If more than one IRD is present, all LNBs are energized. If only one IRD is detected, power sufficient to supply the LNB the IRD has selected is supplied. Identification of which LNB the single IRD has selected may be determined by monitoring the presence of a desired voltage, frequency tone, and or series of frequency tones.

Abstract: A receptacle with an adjusting slot is adapted to receive a mounting lip of the feed assembly. A means for positioning which may include a threaded shaft threaded into a first side of the receptacle that projects into a first side of the mounting lip, is operative to move the mounting lip within the adjusting slot. A bias spring may be positioned between the mounting lip and a second side of the mounting lip, the bias spring biasing the mounting lip against the threaded shaft. Alternatively, the threaded shaft may extend threaded through the mounting lip, longitudinally retained with respect to the receptacle operative to move the mounting lip along the adjusting slot as the threaded shaft is rotated.

Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

Abstract: A control management system provides a plurality of software controllable devices coupled to a network wherein each device has at least one property to be controlled and a plurality of clients for changing the properties of at least one device. An event manager acts as an interface between the clients and the devices. The event manager maintains a persistence store of all the properties being controlled in the home control management system and the current values of the properties. When the client requests status information of the properties it controls, the event manager provides this information to the client thereby avoiding the need for the client to separately query each individual device.

Abstract: A first waveguide to microstrip transition, the waveguide having a top, a bottom, a first sidewall, a second sidewall and a closed end. A transition slot normal to a longitudinal axis of the waveguide intersects the top and the first sidewall. A probe having a 90 degree bend is arranged in the transition slot, a distal end of the probe projecting into the waveguide normal to the top. A proximal end of the probe is coupled to a microstrip on a dielectric substrate. An impedance matching feature may be included projecting from the bottom, proximate the distal end of the probe. A hole may be formed in the dielectric substrate proximate the proximal end of the probe. A second waveguide and transition arrangement may be aligned bottom to bottom with the first waveguide and similarly arranged with a probe coupled to a second microstrip on the dielectric substrate.

Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

Abstract: Filamentous phage particles displaying a ligand on their surface are used to deliver a therapeutic gene to a cell. The ligand is a fusion protein with a phage capsid protein, covalently conjugated to phage particles, or complexed with modified phage particles.

Abstract: Preparations of conjugates of a receptor-binding internalized ligand and a cytocide-encoding agent and compositions containing such preparations are provided. The conjugates contain a polypeptide that is reactive with an FGF receptor, such as bFGF, or another heparin-binding growth factor, cytokine, or growth factor coupled to a nucleic acid binding domain. One or more linkers may be used in the conjugation. The linker is selected to increase the specificity, toxicity, solubility, serum stability, or intracellular availability, and promote nucleic acid condensation of the targeted moiety. The conjugates are complexed with a cytocide-encoding agent, such as DNA encoding saporin. Conjugates of a receptor-binding internalized ligand to a nucleic acid molecule are also provided.